Type 1 Diabetes
Conditions
Brief summary
The Artificial Pancreas Project developed by SUPELEC and the University Hospital of Rennes is focused on the evaluation of an original control algorithm that computes appropriate subcutaneous insulin infusion in response to continuous glucose measurements The results during a 24-hour closed-loop period will be compared with those of the open-loop. The implementation of this algorithm named Error Dynamics Shaping (EDS) requires as a preliminary a phase of identification of the parameters of the model (insulin pharmacokinetics and effect on glucose metabolism) followed by a phase of optimization i.e. a personalized adjustment of the damping parameters of EDS. The present study aims to formalize this procedure of identification/optimization of the parameters of the model and controller EDS. They will be determined in type -1 diabetic patients using insulin therapy and under conditions free from disturbances such as those generated by the glucidic meals, i.e. during a period of glucidic fast. Three variables will determine this procedure: blood glucose, insulin concentration and insulin doses.
Interventions
OTHERBlood samples
The study will be proposed to four patients hospitalized in the Diabetes Unit for a glucidic fast test carried out during 24 hours (lunch, dinner and breakfast). Blood samples will be taken every 20 minutes during 6 hours and 40 minutes to measure plasma insulin concentration and blood glucose. T0 will correspond to the first modification of the insulin basal flow (in more or less) or to the first insulin bolus corrector, usually administered if capillary blood glucose reaches 1.8 g/l. The capillary blood glucose monitoring will be performed every two hours by the nurse.
Sponsors
Rennes University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Type 1 diabetic patients (age : 18-70) * Diabetes duration higher than three years * Insulin pump with Humalog® * Hospitalized for a 24-hour glucidic fast test * Written informed consent
Exclusion criteria
* Pregnancy or nursing * Acute infectious disease * Corticoid treatment * Creatinine clearance \<40 ml/mn * Patients using Apidra® or Novorapid® * People major being the object of a legal protection (safeguard of justice, supervision, trusteeship)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dosage of plasma insulin concentration and blood glucose every 20 minutes during 6 hours and 40 minutes | 3 months | Identification of the eight parameters of the model including the five parameters of the glucose/insulin metabolism (p1, p2, p3, GB and Ib) and the three parameters of the model of subcutaneous insulin absorption Optimization of the four damping parameters of EDS. These coefficients can be tuned to adjust the damping degree of the error dynamics. These procedures of identification and optimization will be carried out under Matlab® and Simulink®. |
Countries
France
Outcome results
None listed